Erratum: Department of Error (The Lancet (2012) 379(9834) (2352–2363), (S0140673612607685), (10.1016/S0140-6736(12)60768-5));The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial

The Lancet

Volumn 379, Issue 9834, 2012, Pages 2352-2363

  Sandercock, Peter ^a   Wardlaw, Joanna M ^a   Lindley, Richard I ^b   Dennis, Martin ^a   Cohen, Geoff ^a   Murray, Gordon ^a   Innes, Karen ^a   Venables, Graham ^c   Czlonkowska, Anna ^d   Kobayashi, Adam ^d   Ricci, Stefano ^e   Murray, Veronica ^f   Berge, Eivind ^g   Slot, Karsten Bruins ^g   Hankey, Graeme J ^h   Correia, Manuel ⁱ   Peeters, Andre ^j   Matz, Karl ^k   Lyrer, Phillippe ^l   Gubitz, Gord ^m   Phillips, Stephen J ^m   Arauz, Antonio ⁿ   Baigent, Colin ^o   Chadwick, David ^p   Tyrrell, Pippa ^q   Lowe, Gordon ^r   Collins, Rory ^o   Bath, Philip ^s   Van Gijn, Jan ^t   Gray, Richard ^o   Hart, Robert ^u   Yusuf, Salim ^u   Clark, Alison ^a   Perry, David ^a   Soosay, Vera ^a   Buchanan, David ^a   Grant, Sheila ^a   Sakka, Eleni ^a   Drever, Jonathan ^a   Walker, Pauli ^a   Herath, Indee ^a   Brown, Ann Leigh ^a   Chmielnik, Paul ^a   Armit, Christopher ^a   Walton, Andrea ^a   Hautvast, Mischa ^a   Lewis, Steff ^a   Heron, Graeme ^a   Odusanya, Sylvia ^a   Linksted, Pam ^a   Kane, Ingrid ^a   Whiteley, Will ^a   Sellar, Robin ^a   White, Philip ^a   Keston, Peter ^a   Farrell, Andrew ^a   Morris, Zoe ^a   Miranda, Hector ^a   Blackwell, Lisa ^v   more..

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e Department of Neurology ASL1 ^*  (Italy)

^f KAROLINSKA INSTITUTE   (Sweden)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h ROYAL PERTH HOSPITAL   (Australia)

ⁱ HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^j CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^k Landesklinikum Donauregion Tulln   (Austria)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

^m DALHOUSIE UNIVERSITY   (Canada)

ⁿ NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p UNIVERSITY OF LIVERPOOL   (United Kingdom)

^q UNIVERSITY OF MANCHESTER   (United Kingdom)

^r UNIVERSITY OF GLASGOW   (United Kingdom)

^s UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^t UTRECHT UNIVERSITY   (Netherlands)

^u MCMASTER UNIVERSITY   (Canada)

^v CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DETERIORATION; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 84862625338     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61408-1     Document Type: Erratum

References (35)

1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol 2007; 6: 182-87.
2. Rothwell PM, Coull AJ, Giles MF, et al, and the Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-33.
3. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8: 355-69.
4. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57.
5. Islam MS, Anderson CS, Hankey GJ, et al. Trends in incidence and outcome of stroke in Perth, Western Australia during 1989 to 2001: the Perth Community Stroke Study. Stroke 2008; 39: 776-82.
6. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; 4: CD000213.
7. Lees KR, Bluhmki E, von Kummer R, et al, and the ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703.
8. Sanossian N, Ovbiagele B. Prevention and management of stroke in very elderly patients. Lancet Neurol 2009; 8: 1031-41.
9. Bembenek J, Kobayashi A, Sandercock P, Czlonkowska A. How many patients might receive thrombolytic therapy in the light of the ECASS-3 and IST-3 data? Int J Stroke 2010; 5: 430-31.
10. Ware JH, Hamel MB. Pragmatic trials\guides to better patient care? N Engl J Med 2011; 364: 1685-87.
11. Sandercock P, Lindley R, Wardlaw J, et al, and the IST-3 collaborative group. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials 2011; 12: 252.
12. Whiteley W, Lindley R, Wardlaw J, Sandercock P, and the IST-3 Collaborative Group. Third international stroke trial. Int J Stroke 2006; 1: 172-76.
13. Sandercock P, Lindley R, Wardlaw J, et al. Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials 2008; 9: 3 7.
14. Sandercock P, Lindley R, Wardlaw J, Whiteley W, Murray G, and the ST-3 collaborative group. Statistical analysis plan for the third International Stroke Trial (IST-3); part of a 'thread' of reports of the trial. Int J Stroke 2012; 7: 186-87.
15. Warlow C, D'Hooghe M, Joos F, et al. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991; 337: 1235-43.
16. Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ 1998; 317: 1170-71.
17. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001; 357: 373-80.
18. König IR, Ziegler A, Bluhmki E, et al, and the Virtual International Stroke Trials Archive (VISTA) Investigators. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke 2008; 39: 1821-26.
19. Langhorne P, Pollock A, and the Stroke Unit Trialists' Collaboration. What are the components of effective stroke unit care? Age Ageing 2002; 31: 365-71.
20. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000; 355: 1670-74.
21. Wardlaw JM, Sellar RJ. A simple practical classification of cerebral infarcts on CT and its interobserver reliability. AJNR Am J Neuroradiol 1994; 15: 1933-39.
22. Wardlaw JM, Farrall AJ, Perry D, et al, and the Acute Cerebral CT Evaluation of Stroke Study (ACCESS) Study Group. Factors influencing the detection of early CT signs of cerebral ischemia: an internet-based, international multiobserver study. Stroke 2007; 38: 1250-56.
23. van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry 1990; 53: 1080-83.
24. Cordonnier C, Potter GM, Jackson CA, et al. Improving inter-rater agreement about brain microbleeds. Development of the Brain Observer MicroBleed Scales (BOMBS). Stroke 2009; 49: 94-99.
25. Farrell C, Chappell F, Armitage PA, et al. Development and initial testing of normal reference MR images for the brain at ages 65-70 and 75-80 years. Eur Radiol 2009; 19: 177-83.
26. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project\1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990; 53: 16-22.
27. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-07.
28. Buyse M, George SL, Evans S, et al. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med 1999; 18: 3435-51.
29. Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J, and the Optimising Analysis of Stroke Trials (OAST) Collaboration. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke 2007; 38: 1911-15.
30. McHugh GS, Butcher I, Steyerberg EW, et al. A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project. Clin Trials 2010; 7: 44-57.
31. Slot KB, Berge E, Dorman P, Lewis S, Dennis M, Sandercock P, and the Oxfordshire Community Stroke Project, the International Stroke Trial (UK), and the Lothian Stroke Register. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 2008; 336: 376-79.
32. Wahlgren N, Ahmed N, Dávalos A, et al, and the SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-82.
33. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010; 11: 85.
34. Lyden PD. In Anticipation of International Stroke Trial-3 (IST-3). Stroke 2012; published online May 3. DOI:10.1161/STROKEAHA.112.656876.
35. Wardlaw J M, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; published online May 23. DOI:10.1016/S0140-6736(12) 60738-7